GenoSight vs Promethease vs SelfDecode vs Nebula 2026

The four contenders, briefly

Promethease. A long-standing variant-report tool with deep ties to the SNPedia wiki. You upload your raw file, it returns a comprehensive report of all variants matched against the wiki's editorial database. Strength: breadth. Weakness: you do most of the prioritization work yourself.

SelfDecode. The largest AI-driven competitor, with a broad topic library, lab integrations, and a chat interface. Strength: scale and content library. Functional difference from us: citation depth and how heavily the synthesis weights your full health context.

Nebula Genomics. Worth flagging at the top: Nebula shut down its consumer service in February 2025. Until shutdown, Nebula sold 30x whole-genome sequencing alongside interpretation rather than reading existing 23andMe/AncestryDNA/MyHeritage files. People still search for "Nebula vs X" comparisons, which is why we're including it — but if you're shopping for whole-genome sequencing today, Sequencing.com is the most direct active replacement.

GenoSight. Reads your existing raw file from 23andMe, AncestryDNA, or MyHeritage, runs three analysis engines (curated lifestyle SNPs, PharmGKB drug-gene interactions, ClinVar disease variants), and synthesizes the findings against a personal-profile context using Anthropic Claude. Strength: contextual synthesis with primary-source citations and a findings-grounded chat.

Functional comparison

Where each service is the right pick

Pick Promethease if you want exhaustive variant-level coverage, you're comfortable doing your own prioritization, and you primarily care about a one-time report rather than ongoing synthesis. The trade-off: a long report you have to read like a research paper.

Pick SelfDecode if you want a large topic library and you've outgrown 23andMe's reports but don't need the deepest possible context-aware synthesis. SelfDecode is the closest functional analog to GenoSight; the differences come down to citation transparency, the depth of personalization, and how the synthesis prioritizes findings against your specific health profile.

You can't pick Nebula anymore. The consumer service was discontinued in February 2025. If you specifically want whole-genome sequencing — meaningfully deeper data than the ~600,000 positions consumer arrays cover — Sequencing.com is the closest active replacement. The trade-off either way is cost and turnaround for the sequencing itself.

Pick GenoSight if you have a raw file from a consumer test, you want context-aware synthesis (the report reasons about your specific medications, family history, and symptoms), and you value a chat where you can ask follow-up questions grounded in your actual findings. Citations are surfaced directly per claim.

A fair note on what's hard to compare

A few things don't fit cleanly in a table.

Citation quality versus citation count. Some services cite many references but lean heavily on review aggregations or secondary sources. Others cite fewer but link directly to primary databases (ClinVar entries, PharmGKB tables, GWAS Catalog studies). Both can be defensible; they're different choices. GenoSight defaults to primary sources at the variant level.

Personalization depth. Most services capture some user context — at minimum, sex and age. The meaningful differentiator is how much of that context flows into the synthesis prompt versus sitting in a sidebar. Without seeing the prompt, this is hard to evaluate from the outside; the pragmatic test is to take the same finding and check whether the recommendation actually changes when you change the context.

Update cadence. Variant interpretations evolve. ClinVar and PharmGKB publish updates regularly; whether a service re-runs your file against new evidence — or expects you to re-pay for re-analysis — is worth checking before you commit.

Pricing

GenoSight — four tiers, one credit-based system

Findings chat is 1 credit per message across all paid plans.

How GenoSight stacks up

Competitor prices change — always confirm before committing. As of May 2026:

Nebula Genomics is no longer a contender — the consumer service was discontinued in February 2025. If you specifically need whole-genome sequencing, Sequencing.com is the closest active replacement.

How to actually decide

Three pragmatic checks before you commit to any of these:

1. Does it accept the file you already have? If yes, that's the cheapest first step regardless of the service.
2. Is the output something you'll actually read? A 200-page Promethease-style report is great if you'll read it; a synthesized 5-page report is great if you won't.
3. Can you ask follow-up questions? A static report ages quickly. A chat that's grounded in your specific findings stays useful.

Related: the practical case for re-analyzing 23andMe with an independent tool, and the structural limits every consumer-array tool shares.

Key takeaways

• Three active consumer DNA analysis services in 2026 are Promethease, SelfDecode, and GenoSight. Nebula Genomics' consumer service was discontinued in February 2025.
• Promethease wins on raw breadth (~$12–25 per report); SelfDecode on topic library ($99/yr to upload existing DNA); GenoSight on context-aware synthesis with primary-source citations.
• GenoSight reads your existing 23andMe / AncestryDNA / MyHeritage file and reasons about findings against a nine-domain health profile — same variant produces different recommendations across different profiles.
• GenoSight pricing: free trial with 250 credits, $11.99/month, $8.33/month billed yearly at $99.99 (full 21-report library), or $229 lifetime with a weekly credit allowance.
• The pragmatic decision criteria: does it accept your existing file, will you actually read the output, and can you ask follow-up questions grounded in your findings.